The Manufacturers Life Insurance Company Buys New Holdings in Insulet Corporation $PODD

Posted by Geri Gentry on Sep 1st, 2026

The Manufacturers Life Insurance Company purchased a new position in Insulet Corporation (NASDAQ:PODD – Free Report) in the second quarter, Holdings Channel reports. The fund purchased 39,965 shares of the medical instruments supplier’s stock, valued at approximately $6,085,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Larson Financial Group LLC increased its position in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Insulet during the 4th quarter worth $26,000. Elyxium Wealth LLC acquired a new position in shares of Insulet during the fourth quarter worth $28,000. DV Equities LLC acquired a new position in shares of Insulet during the fourth quarter worth $28,000. Finally, MV Capital Management Inc. purchased a new position in Insulet in the fourth quarter valued at $29,000.

Insulet Price Performance

Shares of PODD opened at $148.66 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88. The stock has a market cap of $10.31 billion, a PE ratio of 27.79, a price-to-earnings-growth ratio of 1.14 and a beta of 1.10. The firm has a fifty day moving average price of $154.65 and a 200 day moving average price of $179.96.

Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same quarter last year, the company posted $1.17 earnings per share. The business’s quarterly revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, sell-side analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Insider Activity

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.36% of the stock is currently owned by company insiders.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

Positive Sentiment: Insulet’s most recent quarterly results provide a favorable fundamental backdrop: revenue rose 23.5% year over year to $801.7 million and adjusted earnings of $1.66 per share exceeded consensus expectations of $1.47. This strength may be helping offset concerns related to the lawsuit.
Neutral Sentiment: Multiple investor-rights firms—including Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, Levi & Korsinsky, and others—are soliciting affected shareholders ahead of the August 31, 2026 lead-plaintiff deadline. The announcements largely repeat the same litigation information rather than representing separate lawsuits or new company disclosures. Faruqi securities class-action deadline notice
Negative Sentiment: The filed class action alleges that Insulet and certain officers violated federal securities laws by making misleading statements or failing to disclose material information. One notice specifically points to alleged manufacturing problems at the company’s Acton facility, including medical-device corrections affecting millions of Pods, despite SEC filings that described quality-assurance inspections during manufacturing. The allegations have not been proven, but potential damages, legal costs, reputational harm, and further regulatory or operational consequences could pressure valuation. Bronstein class-action announcement Levi and Korsinsky lawsuit notice

Analysts Set New Price Targets

PODD has been the topic of a number of analyst reports. Royal Bank Of Canada cut their price target on Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Raymond James Financial reaffirmed an “outperform” rating and set a $180.00 price objective on shares of Insulet in a research report on Thursday, August 6th. Canaccord Genuity Group dropped their price objective on Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Wall Street Zen cut Insulet from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 9th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $152.00 price target (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $195.40.

View Our Latest Report on Insulet

About Insulet

(Free Report)

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.